Merck shares were rising early Tuesday in response to positive results from a trial of the heart drug that the company is counting on for much of its growth. Patent protection on Keytruda, the cancer ...

Allison DeAngelis is the East Coast biotech and venture capital reporter at STAT, reporting where scientific ideas and money meet. She is also co-host of the weekly biotech podcast, The Readout Loud.

Amgen is refusing U.S. regulators’ request to withdraw an inflammatory disease drug. Elsewhere, Pfizer battled skepticism on ...